A Dose-ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with PAH (BARD Study Phase 2)
Trial ID or NCT#
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary arterial hypertension to determine the recommended dose range and evaluate the change from baseline in 6-minute walk distance (6MWD) following 16 weeks of study participation.
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToVal Scott
Go Back To The Trial